Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-09-04
2007-09-04
Saidha, Tekchand (Department: 1652)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S320100, C435S455000, C530S350000, C530S325000
Reexamination Certificate
active
10650435
ABSTRACT:
The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, ΔF508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous ΔF508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, ΔF508 CFTR.
REFERENCES:
patent: 4980286 (1990-12-01), Morgan et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 2003/0104622 (2003-06-01), Robbins et al.
patent: 2003/0219826 (2003-11-01), Robbins et al.
Meacham et al. └The EMBO Journal, 18(6): 1492-1505 (1999).
Egan et al., 2002, “Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells”,Nature Medicine8: 485-492.
Shwarze et al., 1999, “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse”,Science285:1569-72.
Voce{grave over (r)}o-Akbani et al., 1999, “Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein”,Nat. Med.5:29-33.
Sheppard, DN et al., 1999, “Structure and Function of the CFTR Chloride Channel”, Physiol. Rev 79:S23-45.
Elliot et al., 1999, “Intercellular trafficking of VP22-GFP fusion proteins”, Gene Therapy 6:149-51.
Nagahara et al., 1998, “Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kiplinduces cell migration”,Nat. Med.4:1449-52.
Derossi et al., 1998, “Trojan peptides: the penetratin system for intracellular delivery”,Trends in Cell Biology 8:84-87.
Villaverde et al., 1998, “A cell adhesion peptide from foot-and-mouth disease virus can direct cell targeted delivery of a functional enzyme”,Biotechnology and Bioengineering 59:294-301.
Vives et al., “A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus”,J. Biol. Chem.272:16010-17 (1997).
Elliot & O'Hare, 1997, “Intercellular Trafficking and protein Delivery by a Herpesvirus Structural Protein”,Cell188:223-233.
Moy et al., 1996, “Tat-Mediated Protein Delivery Can Facilitate MHC Class I Presentation of Antigens”,Mol. Biotechnol.6:105-13.
Howard et al., 1995, “Epitope tagging permits cell surface detection of functional CFTR”,Am J. Physiol.269:C1565-76.
Fawell et al., 1994, “Tat-mediated delivery of heterologous proteins into cells”,Proc. Natl. Acad. Sci. USA91:664-668.
Hollenberg et al., 1994, “Multiple promoter elements in the human chorionic gonadotropin β subunit genes distinguish their expression from the luteinizing hormone β gene”,Mol. Cell. Endocrinology106:111-119.
Goldspiel et al., 1993, “Human gene therapy”,Clinical Pharmacy12:488-505.
Tolstoshev, 1993, “Gene therapy, concepts, current trials and future directions”,Ann. Rev. Pharmacol. Toxicol.33:573-596.
Mulligan, 1993, “The Basic Science of Gene Therapy”,Science260:926-932.
Morgan and Anderson, 1993, “Human Gene Therapy”,Annu. Rev. Biochem.62:191-217.
1993, TIBTECH 11(5):155-215.
Miller et al., 1993, “Use of Retroviral Vectors for Gene Transfer and Expression”,Meth. Enzymol.217:581-599.
Kozarsky and Wilson, 1993, “Gene therapy: advenovirus vectors”,Current Opinion in Genetics and Development3:499-503.
Wu and Wu, 1991, “Delivery systems for gene therapy”,Biotherapy3:87-95.
Green & Lowenstein, 1988, “Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat Trans-Activator Protein”,Cell, 55:1179-1188.
Frankel & Pabo, 1988, “Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus”,Cell55:1189-1193.
Wu and Wu, 1987, “Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System”,J. Biol. Chem.262:4429-4432.
Brinster et al., 1982, “Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs”,Nature296:39-42.
Benoist, C. and Chambon, P. 1981, “In vivo sequence requirements of the SV40 early promoter region”,Nature290:304-310.
Wagner et al., 1981, “Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type1”,Proc. Natl. Acad. Sci. U.S.A.78:1441-1445.
Yamamoto et al., 1980, “Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sardoma Virus”,Cell22:787-797.
Frizzell Raymond
Mi Zhibao
Robbins Paul D
Sun Fei
Baker & Botts LLP
Saidha Tekchand
University of Pittsburgh
LandOfFree
Polypeptides for increasing mutant CFTR channel activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides for increasing mutant CFTR channel activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides for increasing mutant CFTR channel activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761703